TME Pharma
TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Our clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned.
|
Updated corporate presentation with ESMO 15 Sept 2024 Oral Presentation data showing statistically significant improvement in survival
|
Press Release2025, June 18 08:00 a.m. TME Pharma announces successful next step in its NOX-E36 ophthalmology strategy with signature of option framework agreement with Singapore Eye Research Institute (SERI) 2025, May 27 08:00 a.m. TME Pharma provides additional details on the debt and warrant agreements announced on 21 May that extend its financial visibility by 12 months 2025, May 26 08:00 a.m. TME Pharma announces convocation of the 2025 annual general meeting of shareholders |
EventsNEAUX CANCER 4th ANNUAL CAGLA CONFERENCE
Aram Mangasarian Latest Analyst ReportInvest Securities |